Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]
Clinical Trials
New data shows consistency of Medtronic MiniMed 780G in different demos, cultures
Medtronic (NYSE:MDT) today announced real-world data demonstrating the global consistency of its MiniMed 780G automated insulin delivery system. The data, according to Medtronic, demonstrates that using the system allows people with diabetes to meet or exceed internationally recommended targets regardless of location. The medtech giant says a barrier to automated insulin delivery (AID) adoption and […]
Abbott study says FreeStyle Libre users on insulin show lower HbA1c levels
Abbott (NYSE:ABT) today announced real-world data associating its FreeStyle Libre CGM with significant HbA1c reductions. The continuous glucose monitor (CGM) played a part in significant reductions in HbA1c, the average glucose levels over a three-month period. It was also associated with a lower rate of hospitalization for people with type 2 diabetes on both multiple […]
Senseonics completes 365-day CGM study cohort
Senseonics (NYSE:SENS) announced today that it completed its ENHANCE pivotal clinical study adult cohort for its 365-day Eversense CGM. Germantown, Maryland-based Senseonics’ ENHANCE study recorded the completed 365-day visit for the final study patient. The study evaluates the year-long implantable continuous glucose monitor in adults. It also has a pediatric cohort (ages 14 to 18), […]
Vaxxas wins $3.7M award to support needle-free typhoid vaccine tech
Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the […]
2-year data backs DarioHealth digital diabetes platform
DarioHealth (Nasdaq:DRIO) today announced new research demonstrating sustainably improved outcomes with its digital diabetes platform. New York-based DarioHealth designed its digital health solutions to combine a clinically intelligent platform with consumer insights. It helps to drive sustainable behavior change to improve the management of chronic conditions, including diabetes. The research, presented at the ADCES23 Annual […]
Advanced NanoTherapies picks up $4M investment for drug-coated balloon development
Advanced NanoTherapies announced today that it collected a $4 million Series A extension from an undisclosed strategic investor. Los Gatos, California-based Advanced NanoTherapies received the investment from a medical device company. It also announced the successful treatment of the first cohort of study participants in its drug-coated balloon trial. The first-in-human trial evaluates initial short-term […]
Orchestra BioMed wins FDA IDE for drug-coated balloon study
Orchestra BioMed (Nasdaq:OBIO) announced today that the FDA granted investigational device exemption (IDE) for its Virtue SAB. The IDE enables the Virtue ISR-US pivotal study. It evaluates Virtue SAB, a novel AngioInfusion balloon for treating artery disease, in treating patients with coronary ISR. New Hope, Pennslyvania-based Orchestra BioMed designed Virtue SAB to enable the protected […]
Know Labs has more positive data for its non-invasive glucose monitor
Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology. Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The […]
Research highlights cost savings from DarioHealth digital diabetes therapeutic
DarioHealth (Nasdaq:DRIO) announced today that a new analysis demonstrated a significant cost reudction for users of its digital therapeutic platform. Sanofi U.S. conducted the analysis, which showed lower costs of care for DarioHealth users compared to non-users with type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings […]
